Abstract Pulmonary Arterial Hypertension (PAH) is the progressive increase in mean
pulmonary arterial pressure (mPAP)(≥ 20 mmHg at rest). Current treatment strategies …

This Review examines the state-of-the-art in the delivery of nucleic acid therapies that are
directed to the vascular endothelium. First, we review the most important homeostatic …

Hypoxic pulmonary hypertension (HPH) is characterized by pulmonary vascular sustained
constriction and progressive remodeling, which are initiated by hypoxia then with hypoxia …

Pulmonary arterial hypertension (PAH) is an unmet clinical need. The lack of models of
human disease is a key obstacle to drug development. We present a biomimetic model of …

Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by the
progressive obstruction of the distal pulmonary arteries (PA). Structural and functional …

Pulmonary hypertension (PH) is a cardiovascular disorder characterized by substantial
morbidity and mortality rates. It is a chronic condition characterized by intricate pathogenesis …

Pulmonary arterial hypertension (PAH) is a rare, serious, and incurable disease
characterized by high lung pressure. PAH-approved drugs based on conventional pathways …

Tbx4 protein, expressed in mesenchyme of the developing lung, contributes to airway
branching and distal lung growth. An association between pediatric onset of pulmonary …

Introduction Treatment of refractory pulmonary arterial hypertension (PAH) is challenging
and rarely the focus of reviews. The purpose of this review is to discuss current treatment …

Pulmonary arterial hypertension (PAH) is a rare but progressive and lethal vascular disease
of diverse etiologies, mainly caused by proliferation of endothelial cells, smooth muscle cells …